Health
Better Coronavirus Stock: AstraZeneca or Johnson & Johnson – The Motley Fool
These two pharma heavyweights are among the many players racing to get a COVID-19 vaccine approved.
The world needs a COVID-19 vaccine, and the number of projects underway to develop one is astounding. Currently, 45 coronavirus vaccine candidates are in human trials, and 11 of those are have reached phase 3, when the vital questions of whether they work in the real world — and if so, how well — will be answered. Russia and China have already approved six vaccines for limited use, but none of those has completed testing in a large-scale phase 3 clinical trial.
The clearest way to evaluate c…
-
Business19 hours agoBattle of the ASX ETFs: Why has VGS outperformed VTS this year?
-
Business18 hours ago5 things to watch on the ASX 200 on Monday 7 April 2025
-
Noosa News15 hours agoMeasles alert: Australia Zoo, Hospital ED, Sushi Hub, Holey Moley Mini Golf and train stations among QLD infection sites
-
Business15 hours ago1 ASX dividend stock down 43% I’d buy right now